First, I wasn’t responding to Gary’s other issues; I spoke specifically about FlaskWorks. I’m not interested in that other stuff he was saying.
Dendritic cells for clinical indications is a burgeoning technology and if you think players in this space aren’t looking for an edge with a critical eye looking forward I don’t think you understand the chess game of entry level biotech.
I believe there are things going on behind the scenes with CRL regarding DCVax. I’m not going to reveal why I think this but I happened upon some signals to that effect. And I believe CRL bought Cognate specifically to become the player in this space of Dendritic Cell manufacturing as part of their forward looking vision. I play in the biotech space because I feel I have a good understanding of the bigger picture of clinical science and where it’s heading. So, I think it’s likely the CRL are interested in the FlaskWorks technology and have the ability to scale that production even further. I don’t know if those talks are happening yet, but if not I believe they most certainly will after TLD in earnest.
And I do believe they’re doing practice runs against the current manufacturing processes. You don’t have to have the actual tumor lysates to do practice runs in the actual Dendritic Cell creation and partial maturation; you can use stand in antigenic molecules to at least get your timing and your ingredients so you you’re not starting flat after Sawston certification. That doesn’t’ mean these runs will count toward equivalency, just that they’re seeing how well the system works and whether they get truly consistent products. That’s what I’d be doing were I running the show (I have a master’s in Manufacturing Engineering)
So, I’m speaking in generalities because the particulars are not yet known. But I feel I know how the various companies involved are thinking because I have experience as a business owner, manufacturer, and Physician. So, maybe “guarantee” was a bit hyperbolic, but I think I’m right and I have reasons beyond what I’ve stated here to believe so.
